No CrossRef data available.
Published online by Cambridge University Press: 31 July 2026
Lamotrigine, widely used in bipolar and depressive disorders, may rarely cause severe cutaneous adverse reactions such as DRESS syndrome. Early recognition is crucial to prevent severe complications.
To report a case of lamotrigine-induced DRESS syndrome and emphasize the importance of early detection and careful monitoring to prevent severe complications.
Case Report: A 19-year-old female treated for recurrent depressive disorder was started on lamotrigine (50 mg/day). Six weeks later, she developed a diffuse pruritic maculopapular rash, fever (38.5°C), cervical lymphadenopathy, and fatigue.
Laboratory tests showed eosinophilia (1200/μL) and moderate hepatic cytolysis (AST 85 U/L, ALT 92 U/L).
The RegiSCAR score suggested probable DRESS. Lamotrigine was promptly discontinued, and systemic corticosteroids were introduced, leading to rapid improvement and resolution of skin lesions within 10 days.
Discussion DRESS is a rare but potentially fatal drug-induced reaction, typically occurring 2–8 weeks after exposure. The risk increases with rapid dose escalation or valproate co-administration.
Management includes immediate drug withdrawal, symptomatic treatment, and systemic corticosteroids in severe cases.
Ce cas souligne la nécessité d’une surveillance étroite lors de l’instauration du traitement par lamotrigine.
Tout signe d’alerte cutané ou systémique doit inciter à une évaluation urgente afin de prévenir les complications graves liées au syndrome DRESS.
None Declared
Comments
No Comments have been published for this article.